tiprankstipranks
Advertisement
Advertisement

JSPR Stock Latest News

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
The FlyJasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
14d ago
JSPR
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway
PremiumCompany Announcements
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway
14d ago
JSPR
Buy Rating on Jasper: Briquilimab’s Strong CSU Efficacy, Favorable Safety, and Competitive Profile Underpin Key Near‑Term Value Driver
PremiumRatings
Buy Rating on Jasper: Briquilimab’s Strong CSU Efficacy, Favorable Safety, and Competitive Profile Underpin Key Near‑Term Value Driver
15d ago
JSPR
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)
PremiumThe Fly
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)
16d ago
JSPR
Jasper Therapeutics assumed with a Neutral at UBS
PremiumThe Fly
Jasper Therapeutics assumed with a Neutral at UBS
23d ago
JSPR
Jasper Therapeutics, Inc. (JSPR) Q4 Earnings Cheat Sheet
PremiumPre-EarningsJasper Therapeutics, Inc. (JSPR) Q4 Earnings Cheat Sheet
1M ago
JSPR
Jasper Therapeutics initiated with a Buy at Rodman & Renshaw
Premium
The Fly
Jasper Therapeutics initiated with a Buy at Rodman & Renshaw
3M ago
JSPR
Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
Premium
Ratings
Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
3M ago
JSPR
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
PremiumCompany Announcements
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
3M ago
8K
JSPR
Jasper Therapeutics reports updated data from briquilimab studies
PremiumThe Fly
Jasper Therapeutics reports updated data from briquilimab studies
3M ago
JSPR
Maintaining Hold on Jasper: Awaiting Critical BEACON CSU Data to Resolve Clinical and Execution Uncertainty
PremiumRatings
Maintaining Hold on Jasper: Awaiting Critical BEACON CSU Data to Resolve Clinical and Execution Uncertainty
3M ago
JSPR
Jasper Therapeutics announces leadership transition and briquilimab update
PremiumCompany Announcements
Jasper Therapeutics announces leadership transition and briquilimab update
3M ago
8K
JSPR
Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO
PremiumThe FlyJasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO
3M ago
JSPR
3 Penny Stocks to Watch Now, 12/4/25
Premium
Market News
3 Penny Stocks to Watch Now, 12/4/25
4M ago
BQ
FTEL
Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab’s Promising Data and Strategic Plans
Premium
Ratings
Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab’s Promising Data and Strategic Plans
4M ago
JSPR
Jasper Therapeutics: Strategic Patient Selection and Consistent Drug Performance Justify Buy Rating
PremiumRatings
Jasper Therapeutics: Strategic Patient Selection and Consistent Drug Performance Justify Buy Rating
4M ago
JSPR
Jasper Therapeutics Reports Positive Phase 1b Study Results
PremiumCompany Announcements
Jasper Therapeutics Reports Positive Phase 1b Study Results
4M ago
8K
JSPR
Jasper Therapeutics reports data from ETESIAN Phase 1b study
PremiumThe Fly
Jasper Therapeutics reports data from ETESIAN Phase 1b study
4M ago
JSPR
Jasper Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Jasper Therapeutics Reports Q3 2025 Financial Results
5M ago
JSPR
Positive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating
PremiumRatingsPositive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating
5M ago
JSPR
Buy Rating Affirmed for Jasper Therapeutics Amid Promising Clinical Trial Results and Proactive Development Efforts
Premium
Ratings
Buy Rating Affirmed for Jasper Therapeutics Amid Promising Clinical Trial Results and Proactive Development Efforts
5M ago
JSPR
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)
Premium
The Fly
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)
5M ago
JSPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >